# LDHA Gene: Structure, Function, and Clinical Significance ## Key Takeaways - The LDHA gene, located at 11p15.1, encodes the A subunit of lactate dehydrogenase, a critical enzyme in anaerobic glycolysis that interconverts pyruvate and lactate, regenerating NAD⁺ essential for ATP production. - Germline mutations in LDHA cause Glycogen Storage Disease type XI (GSD XI), an autosomal recessive disorder characterized by exercise intolerance, myoglobinuria, and characteristic skin lesions. - Somatic overexpression and aberrant regulation of LDHA are hallmarks of numerous cancers, driving the Warburg effect and contributing to tumor progression, immune evasion, and metastasis. - LDHA plays a novel role in epigenetic regulation through histone lactylation, a post-translational modification that links cellular metabolism to gene expression, influencing processes like osteoarthritis development and neural crest differentiation. - LDHA is a therapeutic target, with small-molecule inhibitors like GSK2837808A and FX11 in preclinical development, aiming to disrupt cancer cell metabolism and survival. - Beyond cancer, LDHA is vital for normal physiological processes including spermatogenesis, osteoblast differentiation, and skin wound healing, and its dysregulation is implicated in conditions like pulmonary hypertension and autoimmune uveitis. --- ## Executive Summary & Key Metadata Lactate dehydrogenase A (LDHA) is the gene encoding the A subunit of the tetrameric enzyme lactate dehydrogenase (LDH; EC 1.1.1.27), which catalyzes the reversible interconversion of pyruvate and L-lactate with the concomitant redox exchange of NADH and NAD⁺. Beyond its canonical role in anaerobic glycolysis, LDHA has emerged as a central node in metabolic reprogramming, epigenetic regulation via histone lactylation, immune evasion, and tumor progression. The gene is located on chromosome 11p15.1 and is subject to complex transcriptional, post-transcriptional, and post-translational regulation. Germline mutations in LDHA cause Glycogen Storage Disease type XI (GSD XI), an autosomal recessive disorder characterized by exercise intolerance, myoglobinuria, and characteristic skin manifestations. Somatic overexpression and aberrant regulation of LDHA are hallmarks of numerous malignancies, making it a prime target for therapeutic intervention. | Attribute | Detail | | :--- | :--- | | **HGNC Symbol** | LDHA | | **UniProt Accession** | P00338 | | **Representative PDB ID** | 1I10 (human LDHA tetramer with NADH) | | **Chromosomal Locus** | 11p15.1 (GRCh38: chr11:18,394,563–18,408,425) | | **Primary Molecular Function** | Catalysis of pyruvate ↔ L-lactate interconversion; NADH/NAD⁺ oxidoreductase activity | | **Disease & Pathology Associations** | Glycogen Storage Disease XI (OMIM #612933); multiple cancers (Warburg effect); pulmonary hypertension; osteoarthritis; autoimmune uveitis; noise-induced hearing loss | ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Localization and Gene Structure The human LDHA gene is located on the short arm of chromosome 11, specifically at cytogenetic band 11p15.1. Early mapping studies using in situ hybridization of an LDHA cDNA probe to translocations with breakpoints in 11p13 localized the gene to 11p14→11p15. Subsequent refined mapping placed LDHA at 11p15.1, adjacent to the related LDHC gene, which encodes the testis-specific C subunit. The gene spans approximately 13.9 kilobases of genomic DNA on the plus strand, encompassing 8 exons and 7 introns. The primary transcript is 1,628 nucleotides in length, with a coding sequence of 999 nucleotides that translates into a 332-amino-acid protein. The genomic organization of LDHA is highly conserved across vertebrates, reflecting its essential metabolic function. The exon-intron boundaries align with functional domains of the protein: exon 1 encodes the N-terminal NAD⁺-binding Rossmann fold motif, exons 2–4 encode the substrate-binding domain, and exons 5–8 encode the C-terminal helix that mediates tetramerization. The 5' untranslated region (UTR) is relatively short (~100 bp), whereas the 3' UTR is longer (~500 bp) and contains multiple AU-rich elements (AREs) and microRNA (miRNA) binding sites that regulate mRNA stability and translation. ### 1.2 Promoter Architecture and Transcription Factor Binding The LDHA promoter is a TATA-less, GC-rich promoter that contains multiple Sp1 binding sites, which are essential for basal transcription. The core promoter spans approximately 200 bp upstream of the transcription start site (TSS) and contains binding sites for several transcription factors: - **Hypoxia-Inducible Factor 1 (HIF-1)**: The LDHA promoter contains a canonical hypoxia response element (HRE) with the core sequence 5'-RCGTG-3' at position −40 to −36 relative to the TSS. Semenza et al. demonstrated that HIF-1 binds to this HRE and is essential for hypoxia-induced LDHA transcription. Under normoxic conditions, HIF-1α is hydroxylated by prolyl hydroxylases and targeted for proteasomal degradation; under hypoxia, HIF-1α stabilizes, dimerizes with HIF-1β, and transactivates LDHA. - **c-Myc**: The promoter contains multiple E-box elements (5'-CACGTG-3') that bind c-Myc/Max heterodimers. c-Myc directly transactivates LDHA, linking oncogenic signaling to glycolytic gene expression. The KDM4C/c-Myc/LDHA axis has been shown to drive prostate cancer metastasis. - **Specificity Protein 1 (Sp1)**: Sp1 binds to GC-boxes in the proximal promoter and cooperates with HIF-1 to enhance transcription. - **POU1F1**: The pituitary-specific transcription factor POU1F1 binds to an upstream enhancer region and induces LDHA expression in breast cancer cells, promoting metabolic reprogramming. - **YY1**: The transcription factor Yin Yang 1 binds to the LDHA promoter and induces aerobic glycolysis and proliferation in neuroblastoma cells. - **NAC1**: Nucleus accumbens-associated protein 1 (NAC1) transcriptionally activates LDHA, contributing to HBV immune evasion and hepatocellular carcinoma development. - **STUB1/FOXQ1**: The E3 ubiquitin ligase STUB1 directs FOXQ1-mediated transactivation of the Ldha gene in mouse Sertoli cells, facilitating lactate production essential for spermatogenesis. ### 1.3 Enhancer Elements and Epigenetic Regulation The LDHA locus is regulated by multiple enhancer elements located both upstream and within intronic regions. Chromatin immunoprecipitation sequencing (ChIP-seq) studies have identified enhancer regions marked by H3K27ac and H3K4me1 that are bound by HIF-1, c-Myc, and AP-1 transcription factors. These enhancers loop to the promoter to drive high-level expression in glycolytic tissues such as skeletal muscle, heart, and cancer cells. Epigenetic regulation of LDHA is critical in both development and disease: - **DNA Methylation**: The LDHA promoter contains a CpG island that is subject to methylation-mediated silencing. In a human retinoblastoma cell line, selective promoter methylation of LDHA was associated with an electrophoretic variant of the LDH isoenzyme. Similarly, aberrant methylation of LDHA was observed in a patient with malignant germ cell tumor presenting with high LDH isoenzyme 1. Conversely, demethylation of the LDHA promoter by mogroside V restores glycolytic function in polycystic ovary syndrome (PCOS) granulosa cells. - **Histone Methylation**: KDM6B (JMJD3), a histone H3K27 demethylase, removes repressive H3K27me3 marks from the LDHA promoter, promoting its expression and driving lung metastasis of osteosarcoma. KDM4C, an H3K9 demethylase, similarly activates LDHA through the c-Myc axis in prostate cancer. - **Histone Lactylation**: LDHA-generated lactate serves as a substrate for histone lysine lactylation (Kla), a novel epigenetic mark. LDHA-induced histone H3K18la at the TPI1 promoter drives osteoarthritis development. In hepatocellular carcinoma, LDHA-mediated YAP lactylation promotes YAP dephosphorylation and activation, driving tumor progression. Histone lactylation also couples cellular metabolism with developmental gene regulatory networks in neural crest cells. ### 1.4 Alternative Splicing and Isoforms Alternative splicing of LDHA produces multiple transcript variants. The canonical transcript (ENST00000227236) encodes the 332-amino-acid protein. A second transcript variant lacking exon 6 (ENST00000494459) encodes a truncated protein that lacks part of the substrate-binding domain and is catalytically inactive. This variant is expressed at low levels in normal tissues but may be upregulated in certain cancers. A testis-specific variant, LDHC, is encoded by a separate gene (LDHC) located ~20 kb downstream of LDHA on chromosome 11. LDHC shares high sequence homology with LDHA and LDHB but is expressed exclusively in spermatogenic cells. Interestingly, human LDHA can functionally rescue sperm function in Ldhc-null mice, demonstrating functional redundancy between the A and C subunits. ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Overall Fold and Quaternary Structure LDHA is a homotetrameric enzyme, with each monomer consisting of 332 amino acids and a molecular weight of approximately 36.7 kDa. The enzyme adopts the classic lactate dehydrogenase fold, which is shared among NAD⁺-dependent dehydrogenases. Each monomer is organized into two distinct domains: 1. **NAD⁺-Binding Domain (N-terminal, residues 1–140)**: This domain adopts a Rossmann fold, consisting of a six-stranded parallel β-sheet flanked by four α-helices. The Rossmann fold is the canonical dinucleotide-binding motif, and the GDGQNVVVVGAGVAGIVAG motif (residues 29–47) forms the pyrophosphate-binding loop that coordinates the ADP moiety of NAD⁺. The adenine ring of NAD⁺ is buried in a hydrophobic pocket formed by residues Val-30, Val-32, Val-52, and Ile-54. 2. **Substrate-Binding Domain (C-terminal, residues 141–332)**: This domain adopts an α/β structure with a central six-stranded β-sheet surrounded by α-helices. The active site is located in a cleft between the NAD⁺-binding and substrate-binding domains. Key catalytic residues include: - **Arg-106**: Binds the carboxylate group of pyruvate/lactate. - **His-193**: Acts as the catalytic acid/base, transferring a proton between the substrate and solvent. - **Asp-168**: Positions His-193 through a hydrogen bond network. - **Arg-169**: Stabilizes the transition state. The tetramer is assembled as a dimer of dimers, with the interface between monomers involving both the NAD⁺-binding and substrate-binding domains. The tetramerization interface is stabilized by hydrophobic interactions and hydrogen bonds, with a buried surface area of approximately 3,500 Ų per monomer. The active sites are arranged in pairs at the dimer interfaces, with each active site accepting substrates from adjacent monomers. ### 2.2 Catalytic Mechanism LDHA catalyzes the reversible reduction of pyruvate to L-lactate with the oxidation of NADH to NAD⁺: **Pyruvate + NADH + H⁺ ⇌ L-Lactate + NAD⁺** The reaction proceeds via a ternary complex mechanism with ordered substrate binding: NADH binds first, followed by pyruvate. The catalytic cycle involves: 1. **NADH Binding**: NADH binds to the Rossmann fold domain, positioning the nicotinamide ring in the active site. 2. **Pyruvate Binding**: Pyruvate binds in the substrate pocket, with its carbonyl oxygen oriented toward His-193 and its carboxylate group coordinated by Arg-106. 3. **Hydride Transfer**: The pro-R hydrogen (H4) of the nicotinamide ring is transferred to the carbonyl carbon of pyruvate, while His-193 donates a proton to the carbonyl oxygen. This concerted transfer proceeds through a transition state with substantial oxyanion character, stabilized by Arg-106 and the dipole of helix αF. 4. **Product Release**: The product L-lactate is released, followed by NAD⁺. The equilibrium of the reaction strongly favors lactate formation (Keq ≈ 3.6 × 10⁴ M⁻¹), reflecting the physiological role of LDHA in anaerobic glycolysis. However, under conditions of high lactate and NAD⁺ concentrations, the reverse reaction (lactate oxidation to pyruvate) can proceed, particularly in oxidative tissues. ### 2.3 Substrate Specificity and Isoenzyme Diversity LDHA is one of three LDH subunits (A, B, and C) that assemble into homo- and heterotetramers. The A subunit (LDHA) has a higher affinity for pyruvate (Km ≈ 0.1–0.2 mM) and is more efficient at converting pyruvate to lactate, whereas the B subunit (LDHB) has a higher affinity for lactate and favors the reverse reaction. The C subunit (LDHC) is testis-specific and has intermediate properties. The five LDH isoenzymes (LDH-1 through LDH-5) arise from the random association of A and B subunits: - LDH-1 (B₄): Predominant in heart and erythrocytes; favors lactate oxidation. - LDH-2 (A₁B₃): Found in kidney and pancreas. - LDH-3 (A₂B₂): Found in lung and lymphoid tissue. - LDH-4 (A₃B₁): Found in liver and skeletal muscle. - LDH-5 (A₄): Predominant in skeletal muscle and liver; favors pyruvate reduction. The tissue-specific distribution of LDH isoenzymes reflects the metabolic specialization of each tissue. Tissues with high oxidative capacity (heart, brain) express predominantly LDHB, whereas tissues with high glycolytic capacity (skeletal muscle, liver) express predominantly LDHA. ### 2.4 Post-Translational Modifications LDHA is subject to multiple post-translational modifications that regulate its activity, stability, and subcellular localization: - **Acetylation**: Acetylation of Lys-5 by acetyltransferases reduces LDHA activity and promotes its degradation. Deacetylation by SIRT2 enhances LDHA activity, linking NAD⁺ metabolism to glycolytic flux. - **Phosphorylation**: Phosphorylation at Tyr-10 and Tyr-83 by tyrosine kinases (e.g., FGFR1) enhances LDHA activity and promotes cancer cell proliferation. - **Ubiquitination**: K63-linked ubiquitination by the E3 ligase TRIM28 stabilizes LDHA and promotes bone metastasis of prostate cancer. Conversely, HECW2-mediated ubiquitination promotes LDHA degradation in infantile hemangioma. - **Lactylation**: LDHA itself can be lactylated, although the functional consequences of this modification are still under investigation. ### 2.5 Interactive 3D Visualizer [Interactive 3D Protein Visualizer: Load LDHA (PDB: 1I10)](/tools/protein-structure-viewer?source=direct&pdbId=1I10) The interactive visualizer allows exploration of the LDHA tetramer structure, including the NAD⁺-binding Rossmann fold domains, the substrate-binding clefts, and the tetramerization interfaces. Users can highlight key catalytic residues (His-193, Arg-106, Asp-168), visualize the NADH cofactor, and examine the electrostatic surface potential of the active site. ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 Canonical Role in Glycolysis LDHA catalyzes the final step of anaerobic glycolysis, converting pyruvate to lactate and regenerating NAD⁺ from NADH. This reaction is essential for maintaining glycolytic flux under anaerobic conditions, as it replenishes the NAD⁺ required for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) activity. In tissues with high energy demands (skeletal muscle during exercise, cardiac muscle during ischemia), LDHA ensures continued ATP production through substrate-level phosphorylation. The regulation of LDHA expression and activity is tightly coupled to cellular energy status: - **Hypoxia**: HIF-1α stabilizes under hypoxic conditions and transactivates LDHA, along with other glycolytic enzymes (aldolase A, enolase 1). This coordinate upregulation of glycolytic enzymes ensures ATP production when oxidative phosphorylation is impaired. - **AMPK**: AMP-activated protein kinase (AMPK) senses cellular energy status and can modulate LDHA expression through downstream transcription factors. - **Insulin/IGF-1**: Insulin signaling through PI3K/Akt/mTOR upregulates LDHA expression, promoting glucose utilization and lactate production. ### 3.2 The Warburg Effect and Cancer Metabolism Cancer cells exhibit a profound metabolic reprogramming known as the Warburg effect, characterized by increased glucose uptake and aerobic glycolysis with lactate production even in the presence of oxygen. LDHA is a key effector of the Warburg effect, and its overexpression is observed in a wide range of malignancies: - **Hepatocellular Carcinoma (HCC)**: LDHA is overexpressed in HCC and promotes tumor progression through multiple mechanisms. LDHA-mediated YAP lactylation promotes YAP dephosphorylation and activation, driving HCC growth. NAC1 transcriptional activation of LDHA induces HBV immune evasion, contributing to cirrhosis and HCC development. miR-142-3p and miR-383 inhibit HCC cell proliferation by targeting LDHA. - **Breast Cancer**: POU1F1 induces LDHA expression and metabolic reprogramming in breast cancer. The Trop2 oncogene drives a metabolic gene signature including LDHA that predicts breast cancer outcome. LncRNA TMPO-AS1 promotes triple-negative breast cancer by sponging miR-383-5p to trigger the LDHA axis. - **Pancreatic Ductal Adenocarcinoma (PDAC)**: Matrix stiffness-sensitive LDHA drives autophagy of PDAC via inducing FOXO3 expression and lactylation. LINC01128 facilitates PDAC progression through upregulation of LDHA by targeting miR-561-5p. LDHA is a predictive biomarker for PDAC prognosis and immune cell infiltration. - **Lung Cancer**: LncRNA CAR10 promotes angiogenesis of lung adenocarcinoma by mediating nuclear LDHA to epigenetically regulate VEGFA/C. TOP2A promotes non-small cell lung cancer progression via LDHA-mediated glycolysis and histone lactylation. Blocking LDHA sensitizes glioblastoma cells to radiation and temozolomide. - **Prostate Cancer**: FGF pathway promotes glycolysis by activating LDHA and suppressing LDHB in a STAT1-dependent manner. KDM4C/c-Myc/LDHA signaling suppression inhibits prostate cancer metastasis. TRIM28-LDHA mediated metabolism regulates bone metastatic progression. - **Thyroid Cancer**: LDHA induces EMT gene transcription and regulates autophagy to promote metastasis and tumorigenesis of papillary thyroid carcinoma. - **Colorectal Cancer**: CircRNA PLOD2 promotes tumorigenesis and Warburg effect in colon cancer by the miR-513a-5p/SIX1/LDHA axis. Histone lactylation enhances GCLC expression, promoting chemoresistance of colorectal cancer stem cells through inhibiting ferroptosis. - **T-Cell Acute Lymphoblastic Leukemia (T-ALL)**: Targeting LDHA exerts antileukemic effects on T-ALL. ### 3.3 Histone Lactylation and Epigenetic Regulation A paradigm-shifting discovery in LDHA biology is its role in histone lactylation, a novel post-translational modification that links cellular metabolism to gene expression. Lactate, the product of LDHA catalysis, serves as a substrate for the enzymatic transfer of lactyl groups to lysine residues on histone proteins, particularly H3K18 and H3K23. This modification is catalyzed by p300/CBP acetyltransferases, which exhibit lactyltransferase activity. Histone lactylation has been implicated in: - **Osteoarthritis**: LDHA-induced histone H3K18la at the TPI1 promoter drives osteoarthritis development. - **Hepatocellular Carcinoma**: LDHA-mediated YAP lactylation promotes YAP dephosphorylation and activation. - **Osteoblast Differentiation**: LDHA promotes osteoblast differentiation through histone lactylation. - **Innate Immune Memory**: Long-term histone lactylation connects metabolic and epigenetic rewiring in trained immunity. - **Neural Crest Development**: Histone lactylation couples cellular metabolism with developmental gene regulatory networks. - **Pancreatic Cancer**: Matrix stiffness-sensitive LDHA drives autophagy via inducing FOXO3 expression and lactylation. - **Colorectal Cancer**: Histone lactylation enhances GCLC expression, promoting chemoresistance through inhibiting ferroptosis. The discovery of histone lactylation has expanded the functional repertoire of LDHA beyond its canonical metabolic role, positioning it as a master regulator of the metabolic-epigenetic axis. ### 3.4 Regulation of LDHA by Non-Coding RNAs LDHA expression is tightly regulated by a network of non-coding RNAs, including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs): **MicroRNAs that target LDHA:** | miRNA | Cancer/Context | Effect | Reference | | :--- | :--- | :--- | :--- | | miR-142-3p | Hepatocellular carcinoma | Inhibits aerobic glycolysis and proliferation | | | miR-383 | Hepatocellular carcinoma | Regulates proliferation, invasion, glycolysis | | | miR-34a | Gastric carcinoma | Mediates astragaloside IV effects on glycolysis | | | miR-34b | Pediatric AML | Inhibits cell proliferation | | | miR-1271 | Endometrial cancer | Inhibits proliferation and metastasis | | | miR-638 | Vascular smooth muscle | Represses glycolysis | | | miR-199a-3p | Testicular tumors | Controls aerobic glycolysis via Sp1/LDHA axis | | | miR-561-5p | Pancreatic cancer | Targeted by LINC01128 | | | miR-383-5p | Triple-negative breast cancer | Sponged by TMPO-AS1 | | | miR-513a-5p | Colon cancer | Targeted by circPLOD2 | | **LncRNAs and circRNAs regulating LDHA:** - **LINC01128**: Sponges miR-561-5p to upregulate LDHA in pancreatic cancer. - **TMPO-AS1**: Sponges miR-383-5p to trigger the LDHA axis in triple-negative breast cancer. - **CAR10**: Mediates nuclear LDHA to epigenetically regulate VEGFA/C in lung adenocarcinoma. - **circPLOD2**: Promotes colon cancer via miR-513a-5p/SIX1/LDHA axis. - **hsa_circRNA_403658**: Promotes bladder cancer cell growth through activation of LDHA under hypoxia. ### 3.5 Protein-Protein Interaction Networks LDHA interacts with a diverse array of proteins that modulate its activity, localization, and function: - **HSP90**: Heat shock protein 90 interacts with LSD1 to promote skin wound healing through the c-MYC/LDHA axis. - **TRIM28**: The E3 ubiquitin ligase TRIM28 stabilizes LDHA and promotes bone metastasis of prostate cancer. - **HECW2**: The E3 ubiquitin ligase HECW2 promotes LDHA degradation in infantile hemangioma. - **STUB1**: The E3 ubiquitin ligase STUB1 directs FOXQ1-mediated transactivation of Ldha in Sertoli cells. - **SIRT2**: The deacetylase SIRT2 deacetylates LDHA, enhancing its activity in PCOS. - **STAT1**: STAT1 mediates FGF-induced LDHA activation in prostate cancer. - **FOXO3**: LDHA-induced lactylation of FOXO3 drives autophagy in pancreatic cancer. - **YAP**: LDHA-mediated YAP lactylation promotes YAP dephosphorylation and activation in HCC. ### 3.6 LDHA in Immune Regulation LDHA plays a critical role in immune regulation, both in innate and adaptive immunity: - **Tumor-Associated Macrophages (TAMs)**: LDHA promotes M2-like polarization of TAMs, contributing to the immunosuppressive tumor microenvironment. Nanodrugs incorporating LDHA siRNA inhibit M2-like polarization and amplify autophagy to assist oxaliplatin chemotherapy against colorectal cancer. - **Myeloid-Derived Suppressor Cells (MDSCs)**: High LDHA activity in pancreatic ductal adenocarcinoma promotes uPAR expression in M-MDSCs, contributing to immunosuppression. - **T Cell Function**: LDHA-mediated lactate production restrains antitumor immunity. Tumorous expression of NAC1 restrains antitumor immunity through the LDHA-mediated immune evasion. - **Autoimmune Uveitis**: Single-cell sequencing of the retina shows that LDHA regulates pathogenesis of autoimmune uveitis. - **Noise-Induced Hearing Loss**: LDHA-mediated glycolysis in stria vascularis endothelial cells regulates macrophage function through the CX3CL1-CX3CR1 pathway. - **Trained Immunity**: Long-term histone lactylation connects metabolic and epigenetic rewiring in innate immune memory. ### 3.7 LDHA in Non-Cancer Physiology Beyond cancer, LDHA plays essential roles in normal physiology: - **Spermatogenesis**: LDHA-dependent metabolic programs in Sertoli cells regulate spermiogenesis in mouse testis. STUB1/FOXQ1-mediated LDHA transactivation facilitates lactate production in Sertoli cells. Human LDHA rescues mouse Ldhc-null sperm function. - **Osteoblast Differentiation**: LDHA promotes osteoblast differentiation through histone lactylation. - **Skin Wound Healing**: LSD1 interacting with HSP90 promotes skin wound healing through the c-MYC/LDHA axis. - **Pulmonary Hypertension**: LDHA is a potential therapeutic target for pulmonary hypertension through modulation of endothelial-to-mesenchymal transition. - **Osteoarthritis**: LDHA-induced histone lactylation mediates osteoarthritis development. - **Polycystic Ovary Syndrome**: Nampt/SIRT2/LDHA pathway-mediated lactate production regulates follicular dysplasia in PCOS. Mogroside V restores glycolytic function via LDHA promoter demethylation. ```mermaid flowchart TD A["Hypoxia"] --> B["HIF-1α stabilization"] B --> C["HIF-1β dimerization"] C --> D["HRE binding in LDHA promoter"] D --> E["LDHA transcription"] F["Oncogenic signaling
c-Myc, POU1F1, YY1"] --> G["TF binding to LDHA promoter"] G --> E H["miRNAs
miR-142-3p, miR-383, etc."] --> I["LDHA mRNA degradation"] I --> J["Reduced LDHA protein"] E --> K["LDHA protein"] K --> L["Pyruvate → Lactate"] L --> M["NAD+ regeneration"] M --> N["Sustained glycolysis"] L --> O["Lactate"] O --> P["Histone lactylation"] P --> Q["Epigenetic reprogramming"] Q --> R["Gene expression changes"] K --> S["Protein-protein interactions
TRIM28, HECW2, SIRT2"] S --> T["Stability/Activity modulation"] R --> U["Proliferation, EMT, metastasis"] N --> U T --> U ``` ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Glycogen Storage Disease Type XI (GSD XI) Germline mutations in LDHA cause Glycogen Storage Disease type XI (GSD XI; OMIM #612933), also known as lactate dehydrogenase A deficiency. This is an autosomal recessive disorder characterized by: - **Exercise Intolerance**: Patients experience muscle pain, cramps, and fatigue upon anaerobic exercise. - **Myoglobinuria**: Rhabdomyolysis following strenuous exercise leads to myoglobinuria (dark urine). - **Skin Manifestations**: Characteristic erythematous scaly plaques, particularly on extensor surfaces. - **Elevated CK Levels**: Serum creatine kinase levels are elevated at rest and markedly increased after exercise. Serrano-Lorenzo et al. (2022) characterized two families with novel mutations in the LDHA gene. The clinical, biochemical, and molecular characterization revealed: - **Family 1**: A homozygous missense mutation resulting in a single amino acid substitution that disrupts the active site architecture. - **Family 2**: A compound heterozygous mutation with a frameshift and a splice-site mutation, leading to complete loss of LDHA protein. Both families presented with classic GSD XI phenotypes, including exercise intolerance and myoglobinuria. Biochemical analysis showed markedly reduced LDH activity in muscle biopsies, with a specific reduction in the LDH-5 isoenzyme (A₄). ### 4.2 Pathogenic Variants in ClinVar ClinVar lists multiple pathogenic and likely pathogenic variants in LDHA: | Variant | Type | Clinical Significance | Phenotype | | :--- | :--- | :--- | :--- | | c.526C>T (p.Arg176Cys) | Missense | Pathogenic | GSD XI | | c.860G>A (p.Arg287Gln) | Missense | Pathogenic | GSD XI | | c.448delC (p.Leu150fs) | Frameshift | Pathogenic | GSD XI | | c.733+1G>A | Splice donor | Pathogenic | GSD XI | | c.1A>G (p.Met1Val) | Start loss | Likely pathogenic | GSD XI | The missense mutations cluster in the substrate-binding domain and the tetramerization interface, disrupting either catalytic activity or quaternary structure assembly. The Arg176 residue is located in the active site loop and is essential for substrate binding; its substitution to cysteine abolishes catalytic activity. Arg287 is located at the dimer interface; its substitution to glutamine disrupts tetramer formation. ### 4.3 Somatic Mutations in Cancer Somatic mutations in LDHA are relatively rare in cancer, but copy number gains and overexpression are common. The Cancer Genome Atlas (TCGA) data reveal: - **Amplification**: LDHA is amplified in ~5% of cancers, particularly in ovarian, breast, and lung cancers. - **Missense Mutations**: Recurrent missense mutations at Arg-106, His-193, and Asp-168 (catalytic residues) have been identified, although their functional consequences are not fully characterized. - **Promoter Mutations**: Mutations in the LDHA promoter that create or destroy transcription factor binding sites have been identified in some cancers. ### 4.4 LDHA as a Prognostic and Diagnostic Biomarker Elevated serum LDH levels are a well-established biomarker for tissue damage, hemolysis, and cancer. LDHA-specific measurements provide additional diagnostic and prognostic information: - **Melanoma**: CD39 and LDHA affect the prognostic role of NLR in metastatic melanoma patients treated with immunotherapy. - **Lower-Grade Glioma**: LDHA and SLC16A1 predict prognosis and diagnosis in lower-grade glioma. - **Pancreatic Adenocarcinoma**: LDHA is a predictive biomarker and is associated with immune cell infiltration. - **Clear Cell Renal Cell Carcinoma**: LDHA/LDHB have prognostic value and correlate with tumor-immune infiltration. - **Hepatocellular Carcinoma**: Combined aberrant expression of NDRG2 and LDHA predicts HCC prognosis. ### 4.5 LDHA Polymorphisms and Athletic Performance Single nucleotide polymorphisms (SNPs) in LDHA have been associated with athletic performance in various species: - **Pigeons**: The LDHA/HaeIII polymorphism (g.2582481G>A) is associated with racing performance. LDHA is associated with pigeon survivability during racing competitions. - **Pigs**: A SNP in the porcine LDHA gene is associated with average daily gain and correlated traits in Italian Large White pigs. - **Chickens**: LDHA is among the muscle growth genes mined in chicken. These findings highlight the evolutionary conservation of LDHA function in energy metabolism and its impact on physical performance. ## 5. Host-Pathogen & Viral Interactions ### 5.1 Hepatitis B Virus (HBV) and Hepatocellular Carcinoma LDHA plays a critical role in HBV immune evasion and the progression to cirrhosis and hepatocellular carcinoma: - **NAC1-Mediated LDHA Activation**: NAC1 (nucleus accumbens-associated protein 1) transcriptionally activates LDHA, inducing HBV immune evasion. This leads to the development of cirrhosis and HCC. - **Mechanism**: HBV infection upregulates NAC1, which binds to the LDHA promoter and enhances its transcription. Increased LDHA expression promotes glycolysis and lactate production, creating an immunosuppressive microenvironment that allows HBV to evade immune surveillance. This contributes to chronic infection, cirrhosis, and ultimately HCC development. ### 5.2 Bacterial Pathogens and Metabolic Mimicry The ldhA gene is present in many bacterial species, where it encodes fermentative L-lactate dehydrogenase. While not a direct host-pathogen interaction, the bacterial ldhA gene has been extensively studied for its role in bacterial metabolism and pathogenesis: - **Escherichia coli**: The ldhA gene encoding fermentative lactate dehydrogenase is regulated by multiple transcription factors, including FNR and ArcA, in response to oxygen availability. Deletion of ldhA alters metabolism, gene expression, and metabolic flux distribution. Functional replacement of E. coli ldhA with the L-(+)-lactate dehydrogenase gene (ldhL) from Pediococcus acidilactici has been achieved. - **Corynebacterium glutamicum**: The ldhA gene is positively regulated by the global regulator GlxR and is under the control of positive feedback regulation mediated by LldR. SugR mediates sugar-dependent expression of ldhA. - **Klebsiella pneumoniae**: Deletion of ldhA and aldH genes enhances 1,3-propanediol production. Effects of budC gene knockout and ldhA overexpression on D-lactic acid production have been studied. - **Burkholderia multivorans**: The regulator LdhR and D-lactate dehydrogenase LdhA play roles in carbon overflow and planktonic cellular aggregate formation. ### 5.3 Viral Oncoproteins and Metabolic Reprogramming Several viral oncoproteins exploit LDHA to reprogram cellular metabolism: - **HPV E6/E7**: Human papillomavirus E6/E7 oncoproteins upregulate LDHA expression through HIF-1α stabilization, promoting aerobic glycolysis in cervical cancer cells. - **EBV LMP1**: Epstein-Barr virus latent membrane protein 1 (LMP1) upregulates LDHA through the NF-κB pathway, promoting glycolysis in nasopharyngeal carcinoma. - **HBV HBx**: The HBV X protein (HBx) upregulates LDHA through HIF-1α, contributing to HCC metabolic reprogramming. ### 5.4 Immune Evasion Mechanisms LDHA-mediated lactate production contributes to immune evasion in multiple ways: - **T Cell Suppression**: Lactate secreted by tumor cells inhibits T cell proliferation and cytokine production by acidifying the tumor microenvironment. - **Macrophage Polarization**: Lactate promotes M2-like polarization of tumor-associated macrophages, which suppress antitumor immunity. - **MDSC Accumulation**: High LDHA activity promotes the accumulation of myeloid-derived suppressor cells, which inhibit T cell function. - **NK Cell Inhibition**: Lactate inhibits natural killer (NK) cell activity by reducing their cytotoxic function. ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 Small-Molecule Inhibitors of LDHA LDHA has emerged as a promising therapeutic target, particularly in cancer. Multiple small-molecule inhibitors have been developed: | Inhibitor | Class | Mechanism | Development Stage | Reference | | :--- | :--- | :--- | :--- | :--- | | **GSK2837808A** | Pyrazole sulfonamide | Competitive NADH inhibitor | Preclinical | — | | **FX11** | 3-hydroxy-2-methylpyridine | Competitive NADH inhibitor | Preclinical | — | | **GNE-140** | Aminopyrimidine | Allosteric inhibitor | Preclinical | — | | **NHI-2** | N-hydroxyindole | Competitive NADH inhibitor | Preclinical | — | | **Gossypol** | Polyphenol | Uncompetitive inhibitor | Clinical trials (cancer) | — | | **Oxamate** | Pyruvate analog | Competitive pyruvate inhibitor | Preclinical | — | | **Galloflavin** | Flavonoid | Mixed inhibitor | Preclinical | — | | **PDT-BIPA** | Organic arsenical | LDHA-targeting metabolic inhibitor | Preclinical | | ### 6.2 Natural Compounds Targeting LDHA Several natural compounds have been shown to inhibit LDHA or modulate its expression: - **Cinnamaldehyde**: Inhibits the ErbB2/HSF1/LDHA pathway in bladder cancer cells, exerting anticancer effects. - **Astragaloside IV**: Reverses MNNG-induced precancerous lesions of gastric carcinoma by regulating glycolysis through the miRNA-34a/LDHA pathway. - **Mogroside V**: Restores glycolytic function via LDHA promoter demethylation in PCOS granulosa cells. ### 6.3 Gene Therapy and Genetic Approaches - **CRISPR/Cas9 Gene Editing**: Reactive oxygen species-responsive nanomotors have
## Related Clinical & Scientific Guides * [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway) * [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway) * [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway)